Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of automatic tools for detecting new lesions on therapeutic strategies offered to patients with MS by neurologists.
Merkler B, Masson A, Ferré JC, Bajeux E, Edan G, Michel L, Page EL, Leclercq M, Pegat B, Lamy S, Corre GL, Ahrweiler K, Zagnoli F, Maréchal D, Combès B, Kerbrat A. Merkler B, et al. Among authors: zagnoli f. Mult Scler Relat Disord. 2023 Dec;80:105064. doi: 10.1016/j.msard.2023.105064. Epub 2023 Oct 20. Mult Scler Relat Disord. 2023. PMID: 37866026
Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022.
Lefeuvre C, De Antonio M, Bouhour F, Tard C, Salort-Campana E, Lagrange E, Behin A, Sole G, Noury JB, Sacconi S, Magot A, Nadaj-Pakleza A, Lacour A, Beltran S, Spinazzi M, Cintas P, Renard D, Michaud M, Bedat-Millet AL, Prigent H, Taouagh N, Arrassi A, Hamroun D, Attarian S, Laforêt P; for Pompe Study Group. Lefeuvre C, et al. Neurology. 2023 Aug 29;101(9):e966-e977. doi: 10.1212/WNL.0000000000207547. Epub 2023 Jul 7. Neurology. 2023. PMID: 37419682
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Kishnani PS, Diaz-Manera J, Toscano A, Clemens PR, Ladha S, Berger KI, Kushlaf H, Straub V, Carvalho G, Mozaffar T, Roberts M, Attarian S, Chien YH, Choi YC, Day JW, Erdem-Ozdamar S, Illarioshkin S, Goker-Alpan O, Kostera-Pruszczyk A, van der Ploeg AT, An Haack K, Huynh-Ba O, Tammireddy S, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Kishnani PS, et al. JAMA Neurol. 2023 Jun 1;80(6):558-567. doi: 10.1001/jamaneurol.2023.0552. JAMA Neurol. 2023. PMID: 37036722 Free PMC article. Clinical Trial.
Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study.
Zagnoli F, Leblanc A, Viakhireva-Dovganyuk I, Delabrousse-Mayoux JP, Pouyet A, Ziegler M, Sogni L, Patat M, Bouillot R, Vérin M; APOKADO Group. Zagnoli F, et al. J Neural Transm (Vienna). 2023 Nov;130(11):1463-1474. doi: 10.1007/s00702-023-02609-6. Epub 2023 Mar 2. J Neural Transm (Vienna). 2023. PMID: 36862190 Free PMC article.
Neuromyelitis Optica and Skin.
Misery L, Genestet S, Zagnoli F. Misery L, et al. Among authors: zagnoli f. Dermatology. 2022;238(5):823-828. doi: 10.1159/000522168. Epub 2022 Mar 4. Dermatology. 2022. PMID: 35249011 Free article. Review.
Convergence of patient- and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy.
Sanson B, Stalens C, Guien C, Villa L, Eng C, Rabarimeriarijaona S, Bernard R, Cintas P, Solé G, Tiffreau V, Echaniz-Laguna A, Magot A, Juntas Morales R, Boyer FC, Nadaj-Pakleza A, Jacquin-Piques A, Béroud C, Sacconi S; French FSHD registry collaboration group. Sanson B, et al. Orphanet J Rare Dis. 2022 Mar 2;17(1):96. doi: 10.1186/s13023-021-01793-6. Orphanet J Rare Dis. 2022. PMID: 35236385 Free PMC article.
67 results